Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
CAMBRIDGE, Mass., Feb. 17, 2017 -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) in connection with the collaboration and license agreement with CSL to develop Fc multimer programs, including M230, executed by the Company on January 5, 2017.
With the termination of the applicable waiting period under the HSR Act, the collaboration and license agreement with CSL is effective as of February 17, 2017. Under the license agreement, CSL will pay Momenta a $50 million upfront cash payment within 30 days of the effective date.
Additional details regarding the collaboration can be found in Momenta’s Form 8-K filed with the Securities and Exchange Commission on January 5, 2017.
About Momenta
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for autoimmune indications.
To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release.
Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.
MOMENTA INVESTOR CONTACT: Sarah Carmody Momenta Pharmaceuticals 1-617-395-5189 [email protected] MOMENTA MEDIA CONTACT: Karen Sharma MacDougall Biomedical Communications 1-781-235-3060 [email protected]
